Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Bifendate

Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) [1][2][3][4][5][6].

Product Specifications

Product Name Alternative

DDB

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Atg8/LC3; Autophagy; Cytochrome P450; HBV; p62; P-glycoprotein

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/bifendate.html

Purity

99.92

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C2=C(OC)C1=C(OCO1)C(=C2C(OC)=O)C3=C(C=C(OC)C4=C3OCO4)C(OC)=O

Molecular Formula

C20H18O10

Molecular Weight

418.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Cui S, et al. [Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study]. Zhonghua Yi Xue Za Zhi. 2002 Apr 25;82 (8) :538-40.|[2]Yuan W, et al. Bifendate inhibits autophagy at multiple steps and attenuates oleic acid-induced lipid accumulation. Biochem Biophys Res Commun. 2022 Nov 26;631:115-123. |[3]Xiao Y, et al. Self-emulsifying bifendate pellets: preparation, characterization and oral bioavailability in rats. Drug Dev Ind Pharm. 2013 May;39 (5) :724-32.|[4]Pan SY, et al. Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol. 2006 Dec 15;552 (1-3) :170-5. |[5]Yue S, et al. Hepatoprotective Effect of Apigenin Against Liver Injury via the Non-canonical NF-κB Pathway In Vivo and In Vitro. Inflammation. 2020 Oct;43 (5) :1634-1648.|[6]Zeng Y, et al. Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacol Sin. 2009 Apr;30 (4) :478-84.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light, stored under nitrogen)

Product Datasheet

http://file.medchemexpress.com/batch_PDF/HY-W018791/Bifendate-DataSheet-MedChemExpress.pdf

Product MSDS

http://file.medchemexpress.com/batch_PDF/HY-W018791/Bifendate-SDS-MedChemExpress.pdf

Scientific Category

Reference compound1

Clinical Information

Launched

CAS Number

[73536-69-3]

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

TAGAP antibody - N-terminal region (ARP62158_P050)
ARP62158_P050 100 µL

TAGAP antibody - N-terminal region (ARP62158_P050)

Ask
View Details
Recombinant Cynomolgus 4-1BB/TNFRSF9/CD137 (C-6His)
CB18-500ug 500 µg

Recombinant Cynomolgus 4-1BB/TNFRSF9/CD137 (C-6His)

Ask
View Details
PDLIM5 (G-2) FITC
sc-515621 FITC 200 µg/mL

PDLIM5 (G-2) FITC

Ask
View Details
3- (4-Bromophenyl) oxetane-3-carboxylic acid
OR312082-01 100 mg

3- (4-Bromophenyl) oxetane-3-carboxylic acid

Ask
View Details
3- (4-Bromophenyl) oxetane-3-carboxylic acid
OR312082-02 250 mg

3- (4-Bromophenyl) oxetane-3-carboxylic acid

Ask
View Details
3- (4-Bromophenyl) oxetane-3-carboxylic acid
OR312082-03 1 g

3- (4-Bromophenyl) oxetane-3-carboxylic acid

Ask
View Details